Clinical TrialMay 28, 2026, 11:02 AM
Altimmune's Pemvidutide Shows Significant Lipid & Cardiometabolic Reductions
AI Summary
Altimmune announced new 48-week data from its IMPACT Phase 2b trial for pemvidutide, showing significant reductions in elevated lipids and improvements in multiple cardiometabolic risk factors in MASH patients. The data, presented at EASL 2026, highlighted reductions in triglycerides, total cholesterol, weight, waist circumference, and blood pressure. The safety profile was maintained, with a generally favorable tolerability profile. The company plans to initiate the PERFORMA Phase 3 trial later this year to further evaluate pemvidutide's efficacy and safety in MASH patients.
Key Highlights
- Pemvidutide 1.8 mg reduced triglycerides by -23.7% in patients with elevated baseline values.
- Pemvidutide 1.8 mg reduced total cholesterol by -15.4% in patients with elevated baseline values.
- Pemvidutide 1.8 mg led to a 7.5% weight loss, continuing throughout treatment.
- Pemvidutide 1.8 mg reduced body mass index by -3.0 kg/m2.
- Pemvidutide 1.8 mg reduced waist circumference by -5.3 cm.
- Pemvidutide 1.8 mg improved systolic blood pressure by -4.0 mmHg and diastolic blood pressure by -2.2 mmHg.
- Approximately 1% of pemvidutide patients discontinued treatment due to adverse events.
- 32.4% of pemvidutide 1.8 mg patients achieved both ">="0.5 reduction in ELF and ">="30% reduction in LSM.
Price Impact
More from ALT